Medite Cancer Diagnostics (OTCMKTS:MDIT – Get Rating) and Cytosorbents (NASDAQ:CTSO – Get Rating) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
Analyst Ratings
This is a summary of current recommendations and price targets for Medite Cancer Diagnostics and Cytosorbents, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medite Cancer Diagnostics | 0 | 0 | 0 | 0 | N/A |
| Cytosorbents | 0 | 0 | 1 | 0 | 3.00 |
Cytosorbents has a consensus target price of $5.50, suggesting a potential upside of 58.50%.
Institutional and Insider Ownership
Valuation and Earnings
This table compares Medite Cancer Diagnostics and Cytosorbents’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medite Cancer Diagnostics | N/A | N/A | N/A | N/A | N/A |
| Cytosorbents | $34.69 million | 4.40 | -$32.81 million | ($0.71) | -4.89 |
Medite Cancer Diagnostics has higher earnings, but lower revenue than Cytosorbents.
Volatility & Risk
Medite Cancer Diagnostics has a beta of 56.51, indicating that its share price is 5,551% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Profitability
This table compares Medite Cancer Diagnostics and Cytosorbents’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medite Cancer Diagnostics | N/A | N/A | N/A |
| Cytosorbents | -87.94% | -82.56% | -49.06% |
Summary
Medite Cancer Diagnostics beats Cytosorbents on 5 of the 8 factors compared between the two stocks.
About Medite Cancer Diagnostics
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
About Cytosorbents
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
Receive News & Ratings for Medite Cancer Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medite Cancer Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
